Cable Hill Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Cable Hill Partners’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-267	Closed	-$18K	–	855
2018 Q3	$18K	Hold	267	–	–	0.01%	333
2018 Q2	$20K	Hold	267	–	–	0.01%	335
2018 Q1	$14K	Hold	267	–	–	0.01%	413
2017 Q4	$16K	Buy	+267	New	+$14.9K	0.01%	474

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cable Hill Partners's EGRX Position: Q4 2018 in Review

Cable Hill Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 267 shares — an estimated $18K sold.

Cable Hill Partners first reported a position in EGRX in Q4 2017 and held it in 4 quarters. The position peaked at $20K in Q2 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

Cable Hill Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Cable Hill Partners sold 267 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $18K.
Cable Hill Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Cable Hill Partners's Eagle Pharmaceuticals, Inc. position peaked at $20K in Q2 2018.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Cable Hill Partners's 13F filing for Q4 2018, filed 12 Feb 2019.